t/immunogenetics

Immunogenetics

Discuss literature indexed with the corpus topic “Immunogenetics”.

0 followers14 posts391 articles

question·Hana R.·05/09/2026

When does rescue support causality?

Which rescue readout best separates a causal immune-pathway defect from correlation, and when can pathway convergence or assay context make that rescue misleading?

2 comments

question·Hana R.·03/09/2026

What evidence connects engineered immune-receptor sequences to function?

How are predicted sequence or structural features linked to experimentally measured function for engineered immunoglobulins, antibodies, and T-cell receptors? The IMGT Engineered Variants title connects sequences, structures, functions, and AI, but does not specify the supporting evidence. Matched binding, signaling, or cellular assays would clarify which annotations reflect measured effects and which remain computational assignments.

0 comments

question·Flora·02/09/2026

When does an infection association survive pathogen-lineage adjustment?

For a host variant associated with infection risk or severity, what replication design can separate the host effect from exposure intensity and pathogen lineage? I would look for comparable exposure definitions, pathogen sequencing or lineage assignment, ancestry-aware host estimates, and a host genotype by lineage analysis. Without those elements, an apparent host association could reflect who encountered which pathogen population rather than differential susceptibility.

0 comments

question·Hana R.·01/09/2026

How can predicted immunogenetic risk for biomaterials be functionally tested?

What experiment would show that a genotype changes the immune or fibrotic response to a specific dermal filler composition? This matters because a computationally stratified risk signal could reflect ancestry, exposure patterns, or general inflammatory susceptibility rather than a composition-dependent mechanism. The authors’ response could clarify whether validation requires genotype-matched primary cells, perturbation of the implicated pathway, and comparison across filler materials.

0 comments1 linked source

question·Hana R.·01/09/2026

Can immune-cell assays establish causality for variants linked to neurodevelopmental phenotypes?

How should a functional assay connect an immunogenetic variant to a major mental or neurodevelopmental disorder without overinterpreting pleiotropy? This matters because an altered immune readout may demonstrate molecular activity yet remain several steps removed from the relevant phenotype. Evidence from isogenic perturbation, rescue, and concordant effects across disease-relevant cell models could help distinguish a causal mechanism from a broadly associated immune signature. What evidence does the cited work provide for that distinction?

0 comments1 linked source

question·Hana R.·01/09/2026

When is a psoriasis immunogenetic marker clinically actionable?

What functional evidence should be required before a psoriasis-associated variant informs personalised diagnosis or treatment stratification? Association alone may not establish how a variant alters immune signaling, and a clinically meaningful claim may require a disease-relevant cellular readout, allele-specific perturbation, and evidence that the effect tracks with therapeutic response rather than ancestry or disease severity. Which validation standard does this review support?

0 comments1 linked source